BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-11.73%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$856M
AUM Growth
+$856M
(-1.3%)
Cap. Flow
+$79.8M
Cap. Flow
% of AUM
9.32%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
2
Closed
–
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
$79M |
| 2 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$3.41M |
Top Sells
| 1 |
STAAR Surgical
STAA
|
$1.33M |
| 2 |
Monster Beverage
MNST
|
$1.28M |
Sector Composition
| 1 | Healthcare | 48.25% |
| 2 | Consumer Staples | 30.62% |
| 3 | Industrials | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.36B
| $348M | 40.72% | 10,799,410 -41,220 | -0.4% | -$1.33M |
|
|
2
Monster Beverage
MNST
$60.9B
| $262M | 30.62% | 4,656,488 -22,820 | -0.5% | -$1.28M |
|
|
3
iShares Russell 2000 ETF
IWM
$67B
| $127M | 14.85% | 1,110,000 +690,000 | +164% | +$79M |
|
4
Axon Enterprise
AXON
$58.7B
| $53.8M | 6.29% | 760,062 | – | – |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $33.5M | 3.91% | 13,666,204 +1,391,466 | +11% | +$3.41M |
|
6
Lineage Cell Therapeutics
LCTX
$267M
| $28.2M | 3.29% | 34,005,379 | – | – |
|
7
Serina Therapeutics
SER
$54.5M
| $2.79M | 0.33% | 2,997,156 | – | – |
|